Patrick Colin

A novel orally administered trimebutine compound (<scp>GIC</scp>‐1001) is anti‐nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide‐releasing capacity in mice

Nicolas Cénac, M. Castro, C. Desormeaux et al. · European Journal of Pain · 2015 · 39 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety, Tolerability and Pharmacokinetics of Trimebutine 3-Thiocarbamoylbenzenesulfonate (GIC-1001) in a Randomized Phase I Integrated Design Study: Single and Multiple Ascending Doses and Effect of Food in Healthy Volunteers

Jean-Michel Paquette, Marianne Rufiange, Mirela Iovu Niculita et al. · Clinical Therapeutics · 2014 · 25 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Detection of Tetrahydrobiopterin by LC–MS/MS in Plasma from Multiple Species

Yuwen Zhao, Jerry Cao, Yuan-Shek Chen et al. · Bioanalysis · 2009 · 21 citations

Life Sciences, Biochemistry, Pharmacology +13

Feasibility and Safety of Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia (SANE-01): A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial

Pia Wintermark, Anie Lapointe, Robin H. Steinhorn et al. · The Journal of Pediatrics · 2023 · 12 citations · Full text

Medicine, Neuroscience, Pharmacotherapy +9